Introduction {#Sec1}
============

Type 2 diabetes mellitus (T2DM) is a heterogeneous disease characterized by insulin resistance and defective insulin secretion \[[@CR1]\]. Defective insulin secretion is perhaps the most important pathophysiologic feature of T2DM. Several dipeptidyl peptidase-4 (DPP-4) inhibitors are available for the treatment of T2DM \[[@CR2]\]. DPP-4 inhibitors work by inhibiting DPP-4, which degrades incretin hormones such as glucagon-like peptide (GLP)-1 and glucose-dependent insulinotropic polypeptide, stabilizing the intact (active) forms of the hormones \[[@CR3]\]. DPP-4 inhibitors were first reported to improve glycemic control, insulin secretion, and β-cell function in rodents \[[@CR4]\]. In patients with T2DM, DPP-4 inhibitors were reported to decrease postprandial glucose excursions, fasting plasma glucose (FPG), and hemoglobin A1c (HbA1c), without affecting insulin levels \[[@CR5]\]. In another study, sitagliptin significantly increased insulin levels (21--22%) and decreased glucagon levels (7--14%) at 2 h in an oral glucose tolerance test (OGTT) relative to placebo, but the acute insulin response (30 min) was not significantly increased \[[@CR6]\]. Other studies have also demonstrated that postprandial insulin and C-peptide levels were not significantly affected by sitagliptin \[[@CR7]\]. In that study, the sensitivity of pancreatic β cells to glucose, evaluated as C-peptide at 0 min (CP0)/plasma glucose at 0 min (PG0) and CP30/PG30, did not improve in the sitagliptin or control groups, but CP240/PG240 increased in the sitagliptin group with borderline statistical significance. Another study showed that vildagliptin lowered postprandial glucagon levels by 16%, and that insulin sensitivity and glucose clearance, as determined using glucose clamps, were improved by vildagliptin, but the postprandial insulin levels did not change \[[@CR8]\]. The mean body mass index (BMI) of patients in these studies was 27.5 kg/m^2^ \[[@CR5]\], 29.5 kg/m^2^ \[[@CR6]\], 33.2 kg/m^2^ \[[@CR7]\], and 31.4 kg/m^2^ \[[@CR8]\]. Therefore, these results suggest that DPP-4 inhibitors mainly improved insulin resistance in obese populations, with no or only small improvements in the acute insulin response.

In Japan, approximately half of all patients with diabetes have a genetic predisposition to the disease, and insulin secretion is often impaired in lean patients with diabetes mellitus \[[@CR9], [@CR10]\]. Additionally, Japanese and Asian patients often show reduced β-cell function and it is thought that the innate insulin secretory capacity of East Asians is limited \[[@CR11], [@CR12]\]. The possible instability and vulnerability of canalization due to reduced β-cell function may contribute to the increased prevalence of diabetes in East Asia in recent decades.

A prior study of Japanese patients revealed that once-daily administration of 100-mg sitagliptin for 12 weeks improved the insulinogenic index compared with placebo during a MTT in which the subjects consumed two nutritional bars and a nutritional drink \[[@CR13]\]. However, that study was a phase 2 trial, and sitagliptin was administered before a meal at a dose of 100 mg/day. In Japan, the package insert for sitagliptin recommends a dose of 50 mg/day \[[@CR14]\]. Therefore, the effects of a standard dose of sitagliptin (50 mg/day) on the postprandial metabolic control of patients in real-world settings are currently unknown. Furthermore, Japanese patients usually take sitagliptin after a meal in accordance with the package insert, which is based on the results of peak concentration time (*T*~max~) and apparent terminal half-life (*t*~1/2~) that were not altered significantly by food \[[@CR15]\]. Based on these results, we conducted a study to determine whether a standard dose of sitagliptin (50 mg/day) after a meal could improve the impaired acute insulin response in Japanese patients with T2DM in a real-world setting. We used a meal tolerance test (MTT) that was developed by the Japan Diabetes Society specifically for Japanese patients with T2DM \[[@CR16]\]. The results of the MTT show a strong correlation with those of glucose tolerance tests \[[@CR16]\]. The purpose of this study is to evaluate whether a standard dose of sitagliptin (50 mg/day) after a meal could improve the impaired acute insulin response in Japanese patients with T2DM in a real-world setting.

Methods {#Sec2}
=======

Subjects {#Sec3}
--------

Twenty-one outpatients with T2DM participated in this study at Tottori University Hospital. T2DM was diagnosed based on the criteria of the Japan Diabetes Society \[[@CR17]\]. Patients were eligible if their HbA1c was 6.0--9.0%. These patients were divided into sitagliptin group and control group. This study was a prospective, open-label, non-randomized, clinical study. The patients were consecutively assigned to the control group and the sitagliptin group where the first 10 patients were assigned to the control group and the next 11 patients were assigned to the sitagliptin group. Patients in the sitagliptin group administered sitagliptin at a dose of 50 mg/day once daily after breakfast throughout the treatment period. Patients with pancreatic disease, liver disease, renal failure (estimated Glomerular Filtration Rate \<30 mL/min/1.73 m^2^), or those taking diabetogenic medications such as corticosteroids were excluded from this study. The duration of diabetes and presence of diabetic microangiopathy were retrieved from the patients' medical records. The adverse events were monitored by evaluating liver function, amylase, renal function, common blood count, and hypoglycemic events and abdominal symptoms, and so on. The primary endpoint of the study was the insulinogenic index.

This study was approved by the Ethics Committee of the Faculty of Medicine, Tottori University. All procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and with the Helsinki Declaration of 1975, as revised in 2000 and 2008. Informed consent was obtained from all patients for being included in the study. This study was registered with the University hospital Medical Information Network (identifier: UMIN000011189).

Meal Tolerance Test {#Sec4}
-------------------

After fasting for at least 12 h, the participants visited the hospital in the morning and consumed a test meal prepared by the Japan Diabetes Society (JANEF E460F18: total calories 460 kcal, carbohydrates 56.5 g, fat 18.0 g, protein 18.0 g; Kewpie corporation, Tokyo, Japan) \[[@CR16]\]. Patients consumed the test meal within 15 min, and took 50-mg sitagliptin after the meal. Plasma glucose and insulin were measured at 0 min (fasting), and 30, 60, 120, and 180 min after the test meal. Plasma glucose levels were measured using the Hexokinase/Glucose-6-Phosphate Dehydrogenase method \[[@CR18]\]. Plasma insulin levels were measured using a human chemiluminescent immunoassay kit (Kyowa Medix, Tokyo, Japan). Plasma insulin was defined as immunoreactive insulin (IRI). This MTT is a well-established method that has been used in our hospital in prior studies \[[@CR19]--[@CR21]\].

HbA1c (JDS, Japan Diabetes Society) was measured by high-performance liquid chromatography. However, HbA1c (JDS) values are about 0.4% lower than those of NGSP values, which are the global standard, although measurements of HbAlc in Japan are well calibrated with certified serial reference materials from Lot 1 to Lot 4 using a high resolution ion-exchange HPLC method (KO500). HbA1c (JDS) was converted to National Glycohemoglobin Standardization Program (NGSP) values using the following officially certified equation: $\documentclass[12pt]{minimal}
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                \begin{document}$$ {\text{NGSP }}\left(\% \right) = 1.0 2 \times {\text{JDS }}\left(\% \right) + 0. 2 5 \, \% $$\end{document}$ \[[@CR22]\]. The reverse equation is: $\documentclass[12pt]{minimal}
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Calculation of Insulin Secretion and Resistance Indices {#Sec5}
-------------------------------------------------------

The insulinogenic index was calculated as previously described \[[@CR23]\]: $\documentclass[12pt]{minimal}
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Statistical Analysis {#Sec6}
--------------------

Data are expressed as mean ± standard deviation. The area under the curve (AUC) was calculated according to the trapezoidal rule. We analyzed the variables using the Kolmogorov--Smirnov test. Because ISI and F-IRI showed non-normal distributions, the variables F-IRI, HOMA-IR, ISI, and insulinogenic index were analyzed using non-parametric tests. The other variables were normally distributed. The baseline characteristics were compared between the two groups using unpaired Student's *t* test. F-IRI, HOMA-IR, ISI, and insulinogenic index were compared between the two groups using the Mann--Whitney *U* test. The proportions of patients with microangiopathy were compared using Fisher's exact test. Differences in continuous variables were compared between before and 3 months of treatment using paired Student's *t* test, except for the changes in F-IRI, HOMA-IR, ISI, and insulinogenic index, which were analyzed using the Wilcoxon rank-sum test. The changes in continuous variables from before to 3 months of treatment were compared between the two groups using unpaired Student's *t* test, except for F-IRI, HOMA-IR, ISI, and insulinogenic index, which were compared using the Mann--Whitney *U* test. Values of *P* \< 0.05 were considered statistically significant. SPSS software version 15.0 (SPSS, Chicago, IL, USA) was used for all analyses.

Results {#Sec7}
=======

Patient Characteristics {#Sec8}
-----------------------

The mean age of the patients in sitagliptin group was 67.4 years, the mean BMI was 23.0 kg/m^2^, the mean FPG was 8.05 mmol/L (144.8 mg/dL), the mean HbA1c was 7.73%, and the mean insulinogenic index was 20.1 (Table [1](#Tab1){ref-type="table"}). There were eight males and three females in sitagliptin group, and seven males and three females in the control group. The mean age of the patients in the control group was 64.2 years, the mean BMI was 24.4 kg/m^2^, the mean FPG was 8.12 mmol/L (146.3 mg/dL), the mean HbA1c was 7.20%, and the mean insulinogenic index was 21.8 (Table [1](#Tab1){ref-type="table"}). In the sitagliptin group, four patients were on diet therapy alone and seven were using oral hypoglycemic agents (OHAs), including sulfonylurea (7 patients), α-glucosidase inhibitors (3), biguanides (3), and thiazolidinediones (1). In the control group, two patients were on diet therapy alone and eight were using oral hypoglycemic agents (OHAs), including sulfonylurea (6 patients), α-glucosidase inhibitors (3), biguanides (4), thiazolidinediones (1). None of the patients in either group were using glinides or insulin. The duration of diabetes was 9.8 years in the sitagliptin group versus 7.7 years in the control group. In each group, seven patients had diabetic neuropathy, and two patients had simple diabetic retinopathy. Two patients also had diabetic nephropathy, the two patients in the sitagliptin group had macroalbuminurea, and the two patients in the control group had microalbuminurea. There were no significant differences in any of the baseline characteristics between the sitagliptin and control groups. The adverse events were not detected in the research period.Table 1Comparison of clinical variables before and after treatment in the sitagliptin and control groupsClinical variableSitagliptinControlChange from baseline to 3 monthsBaseline3 months*P\**Baseline3 months*P\**SitagliptinControl*P\*\**Body weight, kg61.5 ± 12.461.2 ± 12.30.5266.1 ± 11.066.1 ± 11.70.75−0.25 ± 1.280.0 ± 1.160.49BMI, kg/m^2^23.0 ± 3.022.9 ± 3.00.5224.4 ± 1.524.4 ± 1.700.84−0.10 ± 0.47−0.01 ± 0.400.53WC, cm83.4 ± 9.084.1 ± 8.20.4986.4 ± 5.388.0 ± 5.40.12+0.77 ± 3.61+1.48 ± 3.120.52FPG, mmol/L\
(mg/dL)8.05 ± 1.56\
(144.8 ± 28.2)7.26 ± 1.04\
(130.6 ± 18.6)0.098.12 ± 1.34\
(146.3 ± 24.5)7.88 ± 1.36\
(141.8 ± 24.5)0.29−0.79 ± 1.38\
(−14.2 ± 25.0)−0.25 ± 0.71\
(−4.5 ± 12.8)0.282-h PPG, mmol/L\
(mg/dL)13.37 ± 2.74\
(240.7 ± 49.3)10.32 ± 1.36\
(185.8 ± 24.4)\<0.00511.50 ± 4.2\
(207.3 ± 76.4)12.0 ± 3.66\
(216.0 ± 65.8)0.58−3.05 ± 2.25\
(−54.9 ± 40.5)+0.48 ± 2.7\
(+8.7 ± 48.7)\<0.05HbA1c (%, NGSP)7.73 ± 0.546.86 ± 0.47\<0.0017.20 ± 1.427.37 ± 1.650.20−0.88 ± 0.60+0.17 ± 0.39\<0.0005F-IRI, pmol/L\
(ng/mL)20.8 ± 9.0\
(3.5 ± 1.5)28.4 ± 16.8\
(4.7 ± 2.8)\<0.0528.7 ± 19.3\
(4.8 ± 3.2)32.9 ± 14.1\
(5.5 ± 2.4)0.36+7.56 ± 8.52\
(+1.26 ± 1.42)+4.14 ± 13.6\
(+0.69 ± 2.27)0.49HOMA-IR1.27 ± 0.711.53 ± 0.40\<0.051.68 ± 1.131.82 ± 0.590.65+0.27 ± 0.33+0.14 ± 0.930.48ISI (Matsuda's index)10.4 ± 5.710.4 ± 7.30.958.15 ± 4.16.63 ± 2.540.34−0.08 ± 4.35−1.54 ± 4.950.72Insulinogenic index20.1 ± 15.736.9 ± 24.1\<0.0521.8 ± 11.522.0 ± 13.90.96+16.7 ± 23.7+0.1 ± 7.9\<0.005AUC glucose, mmol/L·h23.2 ± 3.919.1 ± 2.8\<0.00521.7 ± 5.221.7 ± 4.90.95−4.01 ± 3.50+0.05 ± 2.43\<0.01AUC insulin, pmol/L·h166.9 ± 76.2204.7 ± 114.40.14221.5 ± 103.4228.6 ± 99.80.76+37.7 ± 78.7+7.10 ± 72.50.36AUC insulin/AUC glucose7.2 ± 19.310.7 ± 41.2\<0.0510.2 ± 19.910.5 ± 20.20.63+3.5 ± 0.3+0.5 ± 3.10.12LDL-C, mmol/L3.28 ± 0.563.20 ± 0.630.613.29 ± 0.982.92 ± 0.760.10−0.08 ± 0.57−0.36 ± 0.620.31HDL-C, mmol/L1.67 ± 0.371.57 ± 0.490.121.62 ± 0.261.83 ± 0.590.29−0.09 ± 0.18+0.21 ± 0.610.13TG, mmol/L1.19 ± 0.531.36 ± 0.770.271.63 ± 1.311.36 ± 0.780.24+0.17 ± 0.49−0.28 ± 0.700.10Data are mean ± standard deviation*AUC* area under the concentration--time curve, *BMI* body mass index, *F-IRI* fasting immunoreactive insulin, *FPG* fasting plasma glucose, *HbA1c* hemoglobin A1c, *HDL-C* high-density lipoprotein cholesterol, *HOMA-IR* homeostasis model assessment of insulin resistance, *ISI* insulin sensitivity index, *LDL-C* low-density lipoprotein cholesterol, *NGSP* National Glycohemoglobin Standardization Program, *PPG* postprandial glucose, *TG* triglyceride, *WC* waist circumference\* Paired *t* test, except HOMA-IR, ISI, and insulinogenic index (Wilcoxon rank-sum test)\*\* Unpaired *t* test, except HOMA-IR, ISI, and insulinogenic index (Mann--Whitney *U* test)

The mean FPG did not change significantly from baseline to 3 months of treatment in the sitagliptin group (from 8.05 to 7.26 mmol/L, *P* = 0.09) and the control group (from 8.12 to 7.88 mmol/L, *P* = 0.29) (Table [1](#Tab1){ref-type="table"}). The mean HbA1c decreased significantly in the sitagliptin group (from 7.73 to 6.86%, *P* \< 0.001), but not in the control group (from 7.20 to 7.37%, *P* = 0.20). There were no significant changes in body weight or BMI, and lipid profile in either group.

The mean change in FPG from baseline to 3 months was not significantly different between the sitagliptin and control group (−0.79 vs. −0.25 mmol/L, *P* = 0.28), but HbA1c decreased significantly in the sitagliptin group compared with the control group (−0.88% vs. +0.17%, *P* \< 0.0005; Table [1](#Tab1){ref-type="table"}). The changes in body weight, BMI, and lipid profile were not significantly different between the two groups.

Meal Tolerance Test {#Sec9}
-------------------

There were no significant differences in glucose levels and insulin responses between the two groups at baseline. After 3 months of treatment, the plasma glucose levels at 60, 120, and 180 min were significantly decreased in the sitagliptin (Fig. [1](#Fig1){ref-type="fig"}a), whereas no significant changes were observed in the control group (Fig. [1](#Fig1){ref-type="fig"}b). The plasma insulin levels at 0 and 30 min were significantly increased by sitagliptin (Fig. [2](#Fig2){ref-type="fig"}a), whereas no changes in plasma insulin were found in the control group (Fig. [2](#Fig2){ref-type="fig"}b).Fig. 1Plasma glucose responses during the meal tolerance test. The plasma glucose levels at 60, 120, and 180 min were significantly decreased in the sitagliptin group (**a**), but not in the control group (**b**). \**P* \< 0.05 vs. baseline (paired *t* test)Fig. 2Plasma insulin responses during the meal tolerance test. Plasma insulin levels at 0 and 30 min were significantly increased in the sitagliptin group (**a**), but not in the control group (**b**). \**P* \< 0.05 vs. baseline \[paired *t* test, except for fasting plasma insulin (Wilcoxon rank-sum test)\]

The insulinogenic index increased significantly from baseline to 3 months of treatment in the sitagliptin group (from 20.1 to 36.9, *P* \< 0.05) (Table [1](#Tab1){ref-type="table"}), but not in the control group (from 21.8 to 22.0, *P* = 0.96). Although HOMA-IR increased significantly in the sitagliptin group (from 1.27 to 1.53, *P* \< 0.05), the ISI did not (from 10.4 to 10.4, *P* = 0.95). HOMA-IR and ISI did not significantly change in the control group (HOMA-IR from 1.68 to 1.82, *P* = 0.65; ISI from 8.15 to 6.63, *P* = 0.34). The area under the concentration--time curve (AUC) for glucose decreased significantly in the sitagliptin, but did not change in the control group. The AUC for insulin did not change significantly in either group. The AUC for insulin/AUC for glucose ratio increased significantly in the sitagliptin group, but not in the control group (Table [1](#Tab1){ref-type="table"}).

The change in the insulinogenic index from baseline to 3 months was significantly greater in the sitagliptin group than in the control group (+16.7 vs. +0.1, *P* \< 0.005; Table [1](#Tab1){ref-type="table"}). However, the changes in HOMA-IR and ISI were not significantly different between the two groups. Although the AUC for glucose decreased significantly in the sitagliptin group compared with the control group, the AUC for insulin and the AUC for insulin/AUC for glucose were not significantly different between the two groups.

Discussion {#Sec10}
==========

In this study, treatment with 50 mg/day sitagliptin after a meal for 3 months significantly reduced postprandial glucose levels and increased the insulinogenic index measured during MTTs. These results suggest that sitagliptin improved the acute insulin response in a cohort of Japanese patients with T2DM. In prior studies, DPP-4 inhibitors mainly improved insulin resistance in obese populations, but did not improve the acute insulin response \[[@CR5]--[@CR8]\]. The mean BMIs of patients in these earlier studies ranged from 27.5 to 33.2 kg/m^2^. A recent study revealed that sitagliptin improved the insulinogenic index determined during an OGTT in Korean patients \[[@CR27]\]. The mean BMI of patients in that study was 25.3 kg/m^2^. These results imply that DPP-4 inhibitors improve the acute insulin response in Asian patients with T2DM. The mean BMI was 23.0 kg/m^2^ for the sitagliptin group in our study.

The diabetes epidemic in Asia is characterized by the onset of diabetes at lower BMI levels and younger ages compared with Caucasian populations \[[@CR28]\]. Although the mean BMI is still relatively low in Asian populations, abdominal or central obesity is also highly prevalent, resulting in a widespread "metabolically obese" phenotype. Notable, a meta-analysis revealed that DPP-4 inhibitors lowered HbA1c to a greater extent in studies with ≥50% Asian participants (weighted mean difference −0.92%; 95 % CI −1.03, −0.82) than in studies with \<50% Asian participants (weighted mean difference −0.65%; 95 % CI −0.69, −0.60) \[[@CR29]\]. The meta-analysis found no correlation between BMI and the reduction in HbA1c in studies where the mean BMI was ≥30 kg/m^2^, but BMI was significantly correlated with the reduction in HbA1c in studies where the mean BMI was \<30 kg/m^2^. There were no differences in the change in body weight from baseline between the Asian- and the non-Asian-dominant studies, which suggest that the baseline BMI might influence the glucose-lowering effects of DPP-4 inhibitors. These results suggest that a lower BMI at baseline predicts at greater response to a DPP-4 inhibitor. Accordingly, the difference in BMI among ethnic groups may contribute to the differences in the glucose-lowering response to DPP-4 inhibitors. Another meta-analysis revealed that DPP-4 inhibitors achieved a mean reduction in HbA1c of −0.65% in non-Japanese randomized controlled trials (*n* = 55), and a greater reduction of −1.67% in Japanese randomized controlled trials (*n* = 7) \[[@CR30]\]. The authors suggested that there may be pharmacogenetic or cultural/lifestyle differences that may contribute to the greater reduction in HbA1c in Japanese patients than in studies performed in other countries. A recent article reported that DPP4, a novel adipokine, has a higher release from visceral adipose tissue that is particularly pronounced in obese and insulin-resistant patients \[[@CR31]\]. DPP4 from adipose tissue explants was higher in visceral adipose tissue than in subcutaneous adipose tissue in both lean and obese patients, with obese patients displaying higher DPP4 release than lean controls. These results might be able to explain that DPP4 inhibitor is effective for non-obese patients. Our results also suggest that sitagliptin might be effective in non-obese Japanese and other Asian patients with T2DM.

It has been proposed that the restoration of the early phase of insulin release and postprandial hyperglycemia has important implications on the improvements of metabolic control and reducing the risk of macrovascular complications \[[@CR32]\]. Our results suggest that sitagliptin contributes to improvements in metabolic control and a reduction in cardiovascular risk in patients with T2DM. However, a recent study indicated that the top quartile of the Matsuda ISI was negatively associated with coronary artery calcification, but the insulinogenic index was not associated with coronary artery calcification \[[@CR33]\]. The effects of treating impaired early phase insulin secretion and postprandial hyperglycemia on macroangiopathy are still controversial, and more studies are needed in this field. Moreover, in Japan, approximately half of all patients with diabetes have a genetic predisposition to the disease, and insulin secretion is often impaired in lean patients with diabetes mellitus \[[@CR9], [@CR10]\]. Additionally, Japanese and Asian patients often show reduced β-cell function \[[@CR11], [@CR12]\]. However, a recent study indicated that disposition indices were similar in Japanese and Caucasian patients, and that the differences in insulin sensitivity and β-cell responses between Japanese and Caucasian patients are mainly explained by differences in body composition \[[@CR34]\]. Although further studies are needed to investigate these issues, it is notable that a large proportion of Japanese patients exhibit impaired acute insulin responses. In our study, sitagliptin significantly reduced HbA1c and the AUC for glucose but not AUC for insulin and lipid profile, suggesting that a reduction in glucotoxicity helped to improve insulin secretion. Treatment with sitagliptin also had a significant effect on HOMA-IR, but not on ISI. We suspect that the increase in HOMA-IR was due to an increase in insulin secretion rather than worsening of insulin resistance. The peak concentration time (*T*~max~) for 50 mg/day sitagliptin in Japanese patients is 2.0 h when taken after a meal and 2.5 h when taken before a meal \[[@CR15]\]. Moreover, the half-life (*t*~1/2~) of sitagliptin is 12.3 h when taken after a meal and 12.2 h when taken before a meal \[[@CR15]\]. Therefore, we consider that the insulin responses at 0 and 30 min were due to the acute and chronic effects of sitagliptin. Although we must be careful when interpreting these findings, our results demonstrate that sitagliptin is effective in Japanese patients with T2DM by reducing postprandial hyperglycemia in particular.

Our study had several limitations, including the small number of patients. Because only 11 patients were treated with sitagliptin, our results require confirmation in a larger study. Furthermore, because our study was small and was conducted in an open-label, non-randomized manner, it is difficult to exclude the risk of bias. Design of assignment of patients may have influenced the tendency of difference of postprandial glucose, HbA1c, and F-IRI, although the difference was not significant. The sample size of our study was very small because of the limited numbers of potentially eligible patients at our clinic. Accordingly, the results of this study should be confirmed in a larger study with an appropriate power calculation. The future confirmatory study should involve a blinded, randomized controlled design. Therefore, we added 'a small scale real-world study' in the title. Another potential limitation is that we did not measure incretins or glucagon. However, it is difficult to measure these hormones because they are very unstable and are rapidly degraded. The Japan Diabetes Society established a working group to standardize the measurement of incretins \[[@CR35]\]. They recently proposed that samples should be extracted using a specific procedure to provide more accurate values, and they are currently developing a method to standardize and improve the accuracy of measuring of incretin levels \[[@CR35]\]. In lieu of these recommendations, it is very difficult to measure incretin levels. Nevertheless, we hope to measure these hormones in future studies. It is possible that the different medications used by the subjects modified the insulin response in the MTT. Many of the patients were treated with a sulfonylurea, which might affect the insulin response \[[@CR36]\]. However, in a recent study, treatment with sitagliptin for 60 weeks decreased HbA1c by −0.9% (−10 mmol/mol) when used in combination with metformin and by −1.0% (−11 mmol/mol) in combination with metformin and glimepiride \[[@CR37]\]. These results suggest that treatment with a sulfonylurea did not markedly affect the reduction in HbA1c during treatment with sitagliptin. Because the insulinogenic index was originally derived from the results of OGTTs, it may not be appropriate for assessing acute insulin secretion during MTTs. Indeed, in one study, the insulinogenic index was higher during MTTs than during OGTTs \[[@CR38]\]. However, another study found no difference in the insulinogenic index between OGTTs and MTTs \[[@CR15]\]. Considering the results of these earlier studies, we defined impaired acute insulin secretion during MTT as an insulinogenic index of \<43.2. It was also reported that fat intake enhances GLP-1 secretion \[[@CR39]\]. Therefore, it is possible that the effects of sitagliptin were augmented by the fat content of the mixed meal used in this study. Despite these limitations, we think that our study may aid routine clinical treatment of Japanese and other Asian patients with T2DM.

Conclusion {#Sec11}
==========

Treatment with 50 mg/day sitagliptin after a meal for 3 months improved the acute insulin response and suppressed postprandial hyperglycemia measured during MTTs. Whereas the study is rather small and the design is suboptimal as it is not randomized and not blinded, these results suggest that sitagliptin may be effective in Japanese patients with T2DM, many of whom display impaired acute insulin responses.
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Trial registration: University hospital Medical Information Network identifier \#UMIN000011189.
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